NCT00167609View on ClinicalTrials.gov

Efficacy and Safety of DHEA for Myotonic Dystrophy

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

November 30, 2004

Study Completion Date

December 31, 2006

Conditions
Myotonic Dystrophy
Interventions
DRUG

dehydroepiandrosterone 100 and 400 mg

Trial Locations (10)

92380

Raymond Poincaré Hospital, Garches

Unknown

CHU, Angers

CHU, Bordeaux

CHU, Grenoble

CHU, Lyon

CHU Pouget, Marseille

CHU, Nice

Institut de myologie, Paris

CHU, Strasbourg

CHU, Toulouse

All Listed Sponsors
collaborator

Association Française contre les Myopathies (AFM), Paris

OTHER

collaborator

Assistance Publique - Hôpitaux de Paris

OTHER

lead

University of Versailles

OTHER

NCT00167609 - Efficacy and Safety of DHEA for Myotonic Dystrophy | Biotech Hunter | Biotech Hunter